Dual HER2 Inhibition Strategies in the Management of Treatment-refractory Metastatic Colorectal Cancer: History and Status

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2018 Oct 9

PMID 30294606

Citations 5

Authors

Ozkan Kanat

Hulya Ertas

Burcu Caner

Affiliations

Soon will be listed here.

Abstract

Human epidermal growth factor receptor 2 (HER2) signaling pathway activation has been identified as a contributor to de novo or acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in a small subset of patients with metastatic colorectal cancer (mCRC). Dual anti-HER2-targeted treatment exhibits strong antitumor activity in preclinical models of HER2-positive mCRC, supporting its testing in clinical trials. The HERACLES trial at four Italian academic cancer centers has confirmed the effectiveness of dual blockage of HER2 with trastuzumab plus lapatinib in patients with heavily pretreated HER2-positive mCRC, refractory to the anti-EGFR antibodies cetuximab or panitumumab. Here, we reviewed the preclinical studies exploring the role of HER2 signaling in the development of anti-EGFR therapy resistance and discussed the status of clinical trials assessing the activity of HER2 inhibitors in this setting.

Citing Articles

Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer.

Zhou Y, Wu S, Qu F World J Gastrointest Oncol. 2024; 16(6):2362-2379.

PMID: 38994135 PMC: 11236217. DOI: 10.4251/wjgo.v16.i6.2362.

Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer.

Tan E, Knepper T, Wang X, Permuth J, Wang L, Fleming J Cancers (Basel). 2022; 14(9).

PMID: 35565354 PMC: 9101426. DOI: 10.3390/cancers14092223.

Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects.

Lam M, Lum C, Latham S, Tipping Smith S, Prenen H, Segelov E Cancer Manag Res. 2020; 12:5819-5830.

PMID: 32765085 PMC: 7369412. DOI: 10.2147/CMAR.S213236.

Immune Resistance and EGFR Antagonists in Colorectal Cancer.

Giordano G, Remo A, Porras A, Pancione M Cancers (Basel). 2019; 11(8).

PMID: 31370270 PMC: 6721348. DOI: 10.3390/cancers11081089.

MicroRNA-940 restricts the expression of metastasis-associated gene MACC1 and enhances the antitumor effect of Anlotinib on colorectal cancer.

Wang Y, Zhao M, Zhao H, Cheng S, Bai R, Song M Onco Targets Ther. 2019; 12:2809-2822.

PMID: 31114229 PMC: 6489584. DOI: 10.2147/OTT.S195364.

References

Guo G, Gong K, Wohlfeld B, Hatanpaa K, Zhao D, Habib A . Ligand-Independent EGFR Signaling. Cancer Res. 2015; 75(17):3436-41. PMC: 4558210. DOI: 10.1158/0008-5472.CAN-15-0989. View

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F . Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2016; 3(2):194-201. PMC: 7505121. DOI: 10.1001/jamaoncol.2016.3797. View

Hecht J, Douillard J, Schwartzberg L, Grothey A, Kopetz S, Rong A . Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 2015; 41(8):653-9. DOI: 10.1016/j.ctrv.2015.05.008. View

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F . Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(6):738-746. DOI: 10.1016/S1470-2045(16)00150-9. View

Ramanathan R, Hwang J, Zamboni W, Sinicrope F, Safran H, Wong M . Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 2005; 22(6):858-65. DOI: 10.1081/cnv-200039645. View

Wee P, Wang Z . Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel). 2017; 9(5). PMC: 5447962. DOI: 10.3390/cancers9050052. View

Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A . HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer. 2013; 108(3):668-75. PMC: 3593567. DOI: 10.1038/bjc.2013.4. View

Chan D, Segelov E, Wong R, Smith A, Herbertson R, Li B . Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017; 6:CD007047. PMC: 6481896. DOI: 10.1002/14651858.CD007047.pub2. View

Jeong J, Kim J, Hong Y, Kim D, Kim J, Kim S . HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF. Clin Colorectal Cancer. 2017; 16(3):e147-e152. DOI: 10.1016/j.clcc.2017.01.005. View

10.

Brule S, Jonker D, Karapetis C, OCallaghan C, Moore M, Wong R . Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015; 51(11):1405-14. DOI: 10.1016/j.ejca.2015.03.015. View

11.

Seo A, Kwak Y, Kim D, Kang S, Choe G, Kim W . HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 2014; 9(5):e98528. PMC: 4039475. DOI: 10.1371/journal.pone.0098528. View

12.

Richman S, Southward K, Chambers P, Cross D, Barrett J, Hemmings G . HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2015; 238(4):562-70. PMC: 4785607. DOI: 10.1002/path.4679. View

13.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J . Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3(99):99ra86. PMC: 3268675. DOI: 10.1126/scitranslmed.3002442. View

14.

Zenonos K, Kyprianou K . RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol. 2013; 5(5):97-101. PMC: 3682174. DOI: 10.4251/wjgo.v5.i5.97. View

15.

Therkildsen C, Bergmann T, Henrichsen-Schnack T, Ladelund S, Nilbert M . The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol. 2014; 53(7):852-64. DOI: 10.3109/0284186X.2014.895036. View

16.

Moriarity A, OSullivan J, Kennedy J, Mehigan B, McCormick P . Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016; 8(4):276-93. PMC: 4952023. DOI: 10.1177/1758834016646734. View

17.

Tu J, Yu Y, Liu W, Chen S . Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med. 2014; 9(1):17-24. PMC: 4247305. DOI: 10.3892/etm.2014.2063. View

18.

Rubinson D, Hochster H, Ryan D, Wolpin B, McCleary N, Abrams T . Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2013; 32(1):113-22. PMC: 3775976. DOI: 10.1007/s10637-013-9956-5. View

19.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

20.

Karunagaran D, Tzahar E, Beerli R, Chen X, Ratzkin B, Seger R . ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996; 15(2):254-64. PMC: 449940. View